**Sonnet BioTherapeutics (NASDAQ:SONN) Files 8-K – Entry into a Material Definitive Agreement** **

**

On [Date], Sonnet BioTherapeutics (NASDAQ:SONN) filed an 8-K form with the Securities and Exchange Commission, indicating the company’s entry into a significant definitive agreement.

In the filing, Sonnet BioTherapeutics disclosed that it has entered into a material definitive agreement with [Counterparty Name]. The agreement outlines the terms and conditions of the collaboration between the two entities, including the scope of the partnership, responsibilities of each party, and any financial or operational details deemed relevant.

This agreement represents a strategic move by Sonnet BioTherapeutics [to elaborate on how this aligns with the company’s goals, market position, or growth strategy if applicable].

Further details regarding the agreement, such as specific terms, financial implications, or anticipated outcomes, may be provided by the company in subsequent filings or disclosures.

Investors and stakeholders are encouraged to review the full 8-K filing on the SEC’s website or through Sonnet BioTherapeutics’ investor relations portal for comprehensive information regarding this latest development.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sonnet BioTherapeutics’s 8K filing here.

Sonnet BioTherapeutics Company Profile

Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.